In fact, treatment with 0.1 μM ATRA led to a 25-fold higher CD38 expression in AML cells independent of the culture condition, while healthy control cells only showed a three to sixfold increased expression (Fig. 2a). This evidence concerns the gene CD38 and acute myeloid leukemia.